Press Releases

Seattle, WA - Apr 6, 2011

BRI's Sanda Receives First JDRF Pescovitz Diabetes Research Award

Srinath Sanda, M.D., clinical investigator at Benaroya Research Institute at Virginia Mason (BRI) was awarded the first JDRF Mark Pescovitz Early Career Patient-Oriented Diabetes Research award, representing a five-year grant from the Juvenile Diabetes Research Foundation (JDRF). Sanda will be using the more than $700,000 grant to study immune modulation in Type 1 diabetes. Named for the late Dr. Mark Pescovitz, the award signifies the importance of supporting young clinician scientists dedicated to finding a cure for Type 1 diabetes.

"I am proud and honored to be selected as the first recipient of the research award named in Dr. Pescovitz’s memory," says Sanda. His research will investigate whether modulating inflammatory proteins such as interleukin 1β and specific immune cells called monocytes affects the body’s ability to secrete insulin.

"One of our goals for children and adults newly diagnosed with Type 1 diabetes is to find a way to save their insulin producing cells," says Sanda. "When a person is first diagnosed with Type 1 diabetes, they usually have some functioning insulin producing cells. We’ve found patients who keep these remaining cells longer have a lower rate of complications and better management of their diabetes."
 
Sanda’s research focuses on the diabetes autoimmune process. In addition to participating in the diabetes clinical trials at BRI, Sanda collaborates with bench scientists on translational immunology related to Type 1 diabetes through the JDRF Center for Translational Research at BRI.

"Dr. Sanda is committed to translating novel scientific insights into therapies to prevent and cure Type 1 diabetes," said Richard Insel, M.D., chief scientific officer for JDRF.  "His commitment to clinical investigation models the career of the late Dr. Pescovitz, whose pioneering research helped to create a new understanding of the role of the immune system in Type 1 diabetes."

The JDRF Mark Pescovitz Early Career Patient-Oriented Diabetes Research Award provides support to an investigator who plans to pursue a career in diabetes-related clinical investigation. This award is given to talented young scientists focused on clinical diabetes research to help them become independent clinical diabetes investigators. 

Pescovitz, a JDRF-funded investigator, professor, visionary organ transplant surgeon and research scientist at the Indiana University School of Medicine, died from a tragic car accident on December 12, 2010. His invaluable scientific contributions included advancing the translation of immunology into clinically meaningful improvements in preventing organ rejection after transplantation.

Featured BRI Building Exterior 2024

About Benaroya Research Institute

Benaroya Research Institute (BRI) is a world leader in human immune system research. BRI works to advance the science that will predict, prevent, reverse and cure immune system diseases like allergies, asthma, cancer and autoimmune diseases. BRI accelerates discovery through laboratory breakthroughs in immunology that are then translated to clinical therapies. We believe that a breakthrough in one immune system disease can lead to progress against them all, and work tirelessly toward our vision of a healthy immune system for everyone. BRI is a world-renowned independent nonprofit research institute affiliated with Virginia Mason Franciscan Health and based in Seattle.

To learn more, visit benaroyaresearch.org and connect with us on Facebook, Instagram, Threads, LinkedIn, X and YouTube.